4
Changes in Ownership
NEKTAR THERAPEUTICS Filed Acc 0000950170-25-113692
Chief R&D Officer sold 1,721 shares at an average $33.52 ($57,693)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Zalevsky Jonathan · Chief R&D Officer
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2025-09-04 | Sale : show line 1 in the form 10b5-1 | −793 | $32.43 | $25,717 | 18,390 | D |
| 2025-09-04 | Sale : show line 2 in the form 10b5-1 | −432 | $33.60 | $14,515 | 17,958 | D |
| 2025-09-04 | Sale : show line 3 in the form 10b5-1 | −189 | $34.41 | $6,503 | 17,769 | D |
| 2025-09-04 | Sale : show line 4 in the form 10b5-1 | −307 | $35.69 | $10,957 | 17,462 | D |
| Open-market sales · 1,721 sh · avg $33.52 · $57,693 | ||||||
Loading xslF345X05/ownership.xml…